Sonoma Pharmaceuticals Valuation

Is O8Z undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of O8Z when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate O8Z's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate O8Z's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for O8Z?

Key metric: As O8Z is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for O8Z. This is calculated by dividing O8Z's market cap by their current revenue.
What is O8Z's PS Ratio?
PS Ratio	0.3x
Sales	US$13.55m
Market Cap	US$3.60m

O8Z key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does O8Z's PS Ratio compare to its peers?

The above table shows the PS ratio for O8Z vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	9.8x
B8FK Biofrontera	0.8x	n/a	€16.4m
SBX SynBiotic	7.2x	39.7%	€27.9m
HIGH Cantourage Group	29.4x	38.6%	€57.6m
APPH Apontis Pharma	2x	17.3%	€80.3m
O8Z Sonoma Pharmaceuticals	0.3x	27.4%	€3.6m

Price-To-Sales vs Peers: O8Z is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (12.8x).

Price to Sales Ratio vs Industry

How does O8Z's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

24 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	2.9x	3.4%
O8Z Sonoma Pharmaceuticals	0.3x	27.4%	US$3.60m

24 Companies		Estimated Growth	Market Cap
Industry Avg.	2.9x	21.6%
O8Z Sonoma Pharmaceuticals	0.3x	50.5%	US$3.60m

No more companies

Price-To-Sales vs Industry: O8Z is good value based on its Price-To-Sales Ratio (0.3x) compared to the European Pharmaceuticals industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is O8Z's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

O8Z PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate O8Z's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Aspen Pharmacare Holdings

R74.3b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R9.00

0.6%

5.3%

Pharming Group

€492.8m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.71

0.4%

-33.2%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.45

1.1%

2.9%